Abstract
Platinum and fluoropyrimidine combination chemotherapy forms the basis of first-line systemic treatment for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma, and apart from the addition of trastuzumab for the 15% of patients whose tumours are HER2-positive,1 there has been very little progress over the past two decades. The median overall survival (OS) of patients with advanced disease is around 11 months.2
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
